UTI Diagnostics Study: Patient Advisory Group
A research study to develop a rapid antibiotic susceptibility test for UTIs

Thank you for your interest in the UTI Diagnostics Study Patient Advisory Group.
This study is being facilitated by MicroplateDx. MicroplateDx is currently developing a rapid antibiotic susceptibility test for urinary tract infections (UTI). We are seeking individuals in the Live UTI Free community with lived experience of UTI to help shape the product’s development by joining a Patient Advisory Group led by our team. This is an exciting opportunity to share your experiences and provide valuable insights on what you would like to see in a UTI diagnostic test.
What Is A Patient Advisory Group?
What Will The Study Patient Advisory Group Involve?
We are seeking a Patient Advisory Group (PAG) of 5 to 7 participants, who will help shape the future of UTI diagnostics. As a member of the PAG, you will play a vital role in providing feedback about the overall study, and in guiding the development of two patient focus groups.
The PAG will meet a maximum of once a month throughout the project and all meetings will be held online via Zoom video calls. It is anticipated that each meeting will last no longer than one hour. Discussion may also occur via email between meetings so that we may provide materials for feedback.
Topics we’ll discuss:
- MicroplateDx’s UTI diagnostic test and how it works
- Your personal experiences with UTI and UTI testing
- Defining the inclusion criteria for two patient focus groups
- Providing feedback on materials for the patient focus groups, including participant information sheets
- Exploring the key topics to be covered in the patient focus groups
Will Participants Be Paid?
When Will I Be Expected To Start?
Who Can Apply?
We are looking for 5 to 7 participants, and the role is open to individuals based in the UK. We are looking to involve people with a range of lived experience of UTI and from a range of backgrounds. We ask you to complete a screening questionnaire to tell us about yourself and express your interest in being part of the PAG. We will use this information to identify a group of people with a range of experience who will be invited to join the PAG. Not everyone who applies will be eligible to participate, but for those who are unable to join the PAG on this occasion, there may be other opportunities to help in research about UTI in the future.
To be part of the Patient Advisory Group, you must:
- Be aged 18 years or older
- Be based in the UK (including England, Wales, Scotland and Northern Ireland)
- Have experienced at least one UTI per year OR be a carer for an individual who experiences recurrent UTI
If you are interested in this role, please fill out the screening questionnaire to express your interest..
Do I Need To Have Experience On A Patient Advisory Group?
What Happens If I Can’t Attend A PAG Meeting?
Is There A Waiting List If The Patient Advisory Group Is Full?
How Will The Data I Provide In The Screening Questionnaire Be Used?
What is the UTI Diagnostics Study?
MicroplateDX has received National Institute for Health and Care Research (NIHR) funding to develop and test RapidPlateâ„¢, a rapid, cost-effective antibiotic susceptibility test for urinary tract infections (UTIs) that can be used on site where the patient receives care, for example in a GP clinic. The new test delivers accurate antibiotic recommendations in under one hour, helping to reduce antimicrobial resistance (AMR) by preventing unnecessary or ineffective prescriptions.
Working with other healthcare partners, MicroplateDx will test RapidPlate™ using 500 patient samples and compare it to current gold-standard testing methods. The project also will also gather healthcare professional views on the test and analyse the test’s cost-effectiveness.
With the potential to significantly improve UTI treatment, reduce hospitalisations, and lower NHS costs, RapidPlateâ„¢ is a platform that could transform the way infections are diagnosed and treated, offering fast, more accurate results.
The study commenced in December 2024 with an anticipated end in 2026. Meetings for the Patient Advisory Group will start in April 2025 and continue until November 2025.